PSS20 COST-UTILITY ANALYSIS OF A PRN (AS NEEDED) TREATMENT SCHEDULE WITH RANIBIZUMAB (LUCENTIS) IN WET AMD BASED ON CLINICAL EVIDENCE
Nov 1, 2010, 00:00 AM
10.1016/S1098-3015(11)72649-3
https://www.valueinhealthjournal.com/article/S1098-3015(11)72649-3/fulltext
Section Title :
RESEARCH POSTER ABSTRACTS
Section Order :
807
First Page :
A401
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(11)72649-3&doi=10.1016/S1098-3015(11)72649-3